MAM
Maxus bags IDBI’s Rs 200 million media business
MUMBAI: Maxus has bagged the IDBI media account in Mumbai. The account is estimated to be in the region of Rs 200-250 million. The win comes on the back of several wins the agency has recorded over the last 2-3 months.
Says an elated Maxus India and Asia Pacific MD CVL Srinivas, “We are delighted with these wins. Importantly for us they have come from all three of our main offices of Delhi, Mumbai and Bangalore. We have strong operations in all these centers and today have a diverse client base across each of these units. All these clients are embarking on aggressive growth plans, and we are delighted to be chosen their media partner.”
According to Lodestar media CEO Shashi Sinha, Lodestar lost the agency three months ago. While FCB Ulka was handling the creative, Lodestar was handling the media duties. When the creative duties moved from FCB Ulka to Bates in June, the IDBI media duties moved to Maxus as Bates is a WPP agency.
Srinivas adds, “We have been selective in our pitching this year. After our big account wins last year, our focus has been to look at clients who have the potential to grow in the coming years, and where it makes business sense for us.”
Maxus India won several high profile pitches in 2004, including Britannia, Titan (Planning), Walt Disney, Titan (Buying).
Over the last three months, Maxus has added new businesses that tallies to about Rs 1 billion, according to the agency. These include AMD (microprocessors) in Bangalore, Essar Telecom (Mumbai), GE Money, SBI Cards, Dabur Oral care and the Bill Gates Foundation.
Maxus client portfolio in India includes Hero Honda, Hutch, Britannia, Titan, Seagram, Dabur, Pidilite, VIP luggage, Tata Motors (SUV), Himalaya, Reebok, Hindustan Times and AajTak.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
